Odetiglucan
Phase 2Small molecule
Odetiglucan is one of 65 small molecule programs targeting Colorectal Adenocarcinoma. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
64
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
335 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Medrol
PfizerPreclinical
Byetta
AstraZenecaPreclinical
Odetiglucan
HHiberCell, Inc.
Phase 2
Ayvakit Sprinkle
MMemorial Sloan Kettering Cancer Center
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Active Comparator
ModernaPreclinical
Sulfonylureas
Eli LillyPreclinical
HS-20093
Jiangsu Hansoh Pharmaceutical Co., Ltd.Preclinical
Hyperpolarized 13c Pyruvate
UUniversity of Maryland, Baltimore
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pancreatic Cancer1 trial
Colorectal Adenocarcinoma1 trial
Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma
Recruiting·—·Phase 2·NCT07082439·27 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Odetiglucan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHiberCell, Inc.